EN

科研队伍

您现在的位置: 首页> 科研队伍> 研究员

研究员

张东峰

职 称:研究员

所属科室:合成药物化学研究室

导师类别:硕士生导师

联系方式:zdf@imm.ac.cn

所属重点实验室:活性物质发现与适药化研究北京市重点实验室;
中国医学科学院抗耐药结核创新药物研究重点实验室

个人简介

现任药物所合成室党支部书记,中国药学会抗生素专业委员会青年委员。研究兴趣主要集中在耐药菌、肿瘤和代谢性疾病等领域的创新药物研发,在靶标选择、化合物设计(CADD和虚拟筛选)、结构优化、成药性评价、临床前研究以及临床试验申报等新药研发的各个环节具有丰富的经验。作为课题负责人主持了“重大新药创制”国家科技重大专项子课题、国家自然科学基金和中央公益性科研院所基本科研业务费等项目。作为任务负责人还参加了中国医学科学院医学与健康科技创新工程,药物所与全球结核病药物研发联盟的国际合作项目,北京市科委以及与企业合作的开发项目等多项课题。在药物化学领域权威期刊Journal of Medicinal Chemistry等发表研究论文30余篇,申请和授权发明专利多项。2011年和2013年分别获得中国药学大会暨第十一届中国药师周优秀论文三等奖和第十一届全国医药卫生青年科技论坛优秀论文三等奖。2018年获得中国医学科学院药物研究所“梁周黄于刘青年科技奖”二等奖。

研究方向

1、基于结构或受体的药物分子设计、合成与生物活性研究
2、新药开发及合成工艺研究

发表论文

1. Shihao Cheng,# Yi Zou,# Xi Chen, Jiahao Chen, Bin Wang, Jinying Tian, Fei Ye, Yu Lu, Haihong Huang*, Yongjun Lu*, Dongfeng Zhang*. Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B. European Journal of Medicinal Chemistry, 2023, 258, 115571.
2. Hao Guo, Huahao Wang, Hongyi Zhao and Dongfeng Zhang*. Visible light-promoted synthesis of 4,6a-dihydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-diones via [3+2] cycloaddition reaction of 2H-azirines with maleimides. New Journal of Chemistry, 2023, 47, 5634-5638.
3. Yanan Wu, Hongyi Zhao, Haihong Huang*, Dongfeng Zhang*. Mild synthesis of quinazolines from 2,2,2-trichloroethyl imidates and 2 aminophenyl ketones. Tetrahedron Letters, 2023, 116, 154313.
4. Hongyi Zhao,# Yongxin Gao,# Wei Li,# Li Sheng,# Keli Cui, Bin Wang, Lei Fu, Meng Gao, Ziyun Lin, Xiaowen Zou, Mary Jackson, Haihong Huang,* Yu Lu,* and Dongfeng Zhang*. Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis. Journal of Medicinal Chemistry, 2022, 65(15), 10534-10553.
5. Shihao Cheng,# Qinglin Wang,# Xi Chen, Jiahao Chen, Bin Wang, Dongni Chen, Dong Shen, Jinying Tian, Fei Ye, Yu Lu, Haihong Huang*, Yongjun Lu*, Dongfeng Zhang*. Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors. Bioorganic & Medicinal Chemistry, 2022, 73, 117006.
6. Haijia Lu, Huahao Wang, Hongyi Zhao, Dongfeng Zhang*. Recent advances in oxazolidinones as antituberculosis agents. Future Medicinal Chemistry, 2022, 14(15), 1149-1165.
7. Hongyi Zhao,# Shengnan Li,# Shihao Cheng, Ziyun Lin, Dongfeng Zhang* and Haihong Huang*, A mild and metal-free synthesis of chiral 2,3-dihydro-3-hydroxymethyl-1,4-benzoxazines, Tetrahedron, 2021, 93, 132304.
8. Xiao Wang,# Wenting Zhao,# Bin Wang, Wei Ding, Hao Guo, Hongyi Zhao, Jianzhou Meng, Sihan Liu, Yu Lu, Yishuang Liu*, Dongfeng Zhang*. Identification of inhibitors targeting polyketide synthase 13 of Mycobacterium tuberculosis as antituberculosis drug leads. Bioorganic Chemistry, 2021, 114, 105110.
9. Dongfeng Zhang,# Peng Li,# Yongxin Gao, Yaoyao Song, Yaqin Zhu, Hong Su, Beibei Yang, Li Li, Gang Li, Ningbo Gong, Yang Lu, Huanjie Shao,* Chunrong Yu,* and Haihong Huang*. Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. Journal of Medicinal Chemistry, 2021, 64(11), 7434-7452
10. Yongqi Wu, Bin Wang, Haijia Lu, Hongyi Zhao, Beibei Yang, Li Li, Yu Lu, Dongfeng Zhang*, Ning Sun*, Haihong Huang*. Identification of novel tricyclic benzo[1,3]oxazinyloxazolidinones as potent antibacterial agents with excellent pharmacokinetic profiles against drug-resistant pathogens. Journal of Medicinal Chemistry, 2021, 64(6), 3234-3248
11. Hongyi Zhao, Bin Wang, Lei Fu, Gang Li, Haijia Lu, Yuke Liu, Li Sheng, Yan Li, Baoxi Zhang, Yang Lu, Chen Ma, Haihong Huang*, Dongfeng Zhang*, and Yu Lu*. Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis. Journal of Medicinal Chemistry, 2020, 63(17), 9316-9339
12. Hongyi Zhao, Wenting Zhao, Shihao Cheng, Haijia Lu, Dongfeng Zhang*, and Haihong Huang*, Efficient and stereoselective one-pot synthesis of benzo[b]oxazolo[3,4-d][1,4]oxazin-1-ones, RSC Advances, 2020, 10, 24037-24044
13. Wenting Zhao, Bin Wang, Yuke Liu, Lei Fu, Li Sheng, Hongyi Zhao, Yu Lu, Dongfeng Zhang*, Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis. European Journal of Medicinal Chemistry, 2020, 189, 112075
14. Dongfeng Zhang, Yun Lin, Xi Chen, Wenting Zhao, Dongni Chen, Meng Gao, Qinglin Wang, Bin Wang, Haihong Huang*, Yongjun Lu*, Yu Lu*. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold. Bioorganic Chemistry, 2019, 85, 229-239
15. Meng Gao, Wenting Zhao, Hongyi Zhao, Ziyun Lin, Dongfeng Zhang* and Haihong Huang*. An efficient and facile access to highly functionalized pyrrole derivatives. Beilstein Journal of Organic Chemistry, 2018, 14, 884-890
16. Hongyi Zhao,# Yu Lu,# Li Sheng, Zishuo Yuan, Bin Wang, Weiping Wang, Yan Li, Chen Ma, Xiaoliang Wang, Dongfeng Zhang*, and Haihong Huang*. Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant tuberculosis. ACS Medicinal Chemistry Letters, 2017, 8 (5), 533-537
17. Dongfeng Zhang,# Yu Lu,# Kai Liu, Binna Liu, Jingbin Wang, Gang Zhang, Hao Zhang, Yang Liu, Bin Wang, Meiqin Zheng, Lei Fu, Yanyan Hou, Ningbo Gong, Yang Lv, Chun Li, Christopher B. Cooper, Anna M. Upton, Dali Yin, Zhenkun Ma*, and Haihong Huang*. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. Journal of Medicinal Chemistry, 2012, 55(19), 8409-8417

专著

专利

1. 张东峰、黄海洪、赵文婷,色满酮类化合物及其制备方法和用途,ZL201911014471.7
2. 黄海洪、张东峰、赵红义,含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途, ZL201810234583.2
3. 黄海洪、张东峰、高永鑫、林紫云、赵红义、高猛、马辰、李燕、盛莉,吡咯-2-甲酰胺类化合物及其制备方法和用途,ZL201880056468.9
4. 张东峰、黄海洪、李春、尹大力、林紫云、马辰、王迷娟、张猛、兰培、赵立敏,吡法齐明的制备方法,ZL201711054900.4
5. 黄海洪、张东峰、林紫云、王晓良、彭英,硝酸2-(4-甲基噻唑-5-基)乙酯盐酸盐的制备方法,ZL201611214110.3
6. 黄海洪、张东峰、赵红义,含四氢吡啶的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途,ZL201611212328.5
7. Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko. Substituted phenyloxazolidinones and their antimicrobial activity, US10550092
8. Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang. Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity. US87162922
9. 余春荣、黄海洪、张东峰、李鹏,蛋白激酶抑制剂,ZL201580045932.0
10. 黄海洪、余春荣、张东峰、李鹏,蛋白激酶抑制剂,ZL201380038289.X
11. Chunrong Yu, Haihong Huang, Dongfeng Zhang, Peng Li. Protein kinase inhibitors, US9174996

科技奖励